Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2021 · 10-Q
Revenue$46.59M$46.59M+40.5% vs Q1 2020 Net Income$18.11M$18.11MN/M vs Q1 2020 EPS Diluted$1.05$1.05N/M vs Q1 2020 Operating Income$4,715,000+24.5% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Free Cash Flowderived$7,350,000— Margins · derivedOperating margin10.1%−1.3 pt vs Q1 2020
Net margin38.9%+111.6 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end